Genentech

Genentech, part of pharma giant Roche, has been developing a pipeline of neuroscience drugs at a time when other pharmaceutical companies have largely left the space. Among those drugs are two treatments for Alzheimer's disease, a condition that hasn't had a new treatment for 15 years and has faced a number of ...

Treatment with Ocrevus (ocrelizumab) shows sustained efficacy and an ability to improve cognition in patients with relapsing multiple sclerosis (MS), according to data being presented by Genentech, the drug's developer. The company will detail these findings in a series of oral and poster sessions at the ...

Seattle biotech Kineta will partner with big biotech company Genentech to make and sell a drug used to treat chronic pain, in a deal that could be worth more than $359 million for the Seattle company. Kineta announced Monday it made a deal with San Francisco-based Genentech to develop Kineta's ...

Kineta Chronic Pain LLC has inked a drug collaboration deal with pharmaceutical giant Genentech to develop non-opioid chronic pain treatment. The Seattle-based biotech, a subsidiary of Kineta Inc., received an undisclosed upfront payment as part of the deal and is eligible for milestone payments up to ...

More than two years after Genentech passed over its option to acquire Constellation Pharmaceuticals, the immuno-oncology company raised $100 million that will bankroll a cancer epigenetics candidate through clinical trials, as well as advance several pipeline prospects. Its work is based on epigenetics, ...

The five adults with hemophilia A who died while using Hemlibra (emicizumab-kxwh) to treat their disease did not die of causes related to the treatment, manufacturer Genentech said in a statement. “In each of these cases, the assessment of the treating physician or investigator was that the cause of death ...

The Hemophilia Federation of America has put out a statement noting that Roche alerted them of the deaths of 5 patients who were taking their new drug Hemlibra, calculated to be the biggest single drug launch of the year. And according to Roche, the alert followed the death of two patients earlier this year ...

Young joined Genentech in 2006, a time when the historically antibody-focused firm was trying to establish equal expertise in small molecules. Michael Varney, who now leads R&D at Genentech, had championed bringing her into the fold, and she started out in medicinal chemistry. As the team grew, ...

Genentech researchers have found a chink in the armor of drug-resistant, gram-negative bacteria called the BamA enzyme, which is found in the bugs' outer membrane. And they've found a way to attack this protein with an antibody—an approach that they say could pave the way for a new class of ...

Law360 (April 24, 2018, 8:42 PM EDT) -- Genentech on Monday urged the Federal Circuit to affirm a California federal judge's tossing of claims that it induced others to infringe a patent covering treatments for conditions such as breast cancer, arguing that not only was the lower court correct to do so, but that it should have ...

Law360 (April 24, 2018, 8:42 PM EDT) -- Genentech on Monday urged the Federal Circuit to affirm a California federal judge's tossing of claims that it induced others to infringe a patent covering treatments for conditions such as breast cancer, arguing that not only was the lower court correct to do so, but that it should have ...